Compare RTX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | SNY |
|---|---|---|
| Founded | 1934 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.3B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | RTX | SNY |
|---|---|---|
| Price | $186.45 | $48.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $182.15 | $61.50 |
| AVG Volume (30 Days) | ★ 4.4M | 2.4M |
| Earning Date | 01-27-2026 | 01-29-2026 |
| Dividend Yield | 1.46% | ★ 3.31% |
| EPS Growth | 38.64 | ★ 105.93 |
| EPS | 4.87 | ★ 8.67 |
| Revenue | ★ $85,988,000,000.00 | $53,890,648,839.00 |
| Revenue This Year | $8.82 | $1.73 |
| Revenue Next Year | $6.24 | $6.49 |
| P/E Ratio | $38.14 | ★ $5.58 |
| Revenue Growth | ★ 8.79 | N/A |
| 52 Week Low | $112.27 | $44.62 |
| 52 Week High | $193.79 | $60.12 |
| Indicator | RTX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 45.33 |
| Support Level | $182.17 | $47.17 |
| Resistance Level | $188.00 | $48.74 |
| Average True Range (ATR) | 3.82 | 0.52 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 43.20 | 52.96 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.